Company Reports Q1 Revenue of $8.0M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy RPID?
Reports Q1 revenue $8.0M, consensus $7.6M. Cash, cash equivalents, short-term investments, and restricted cash were approximately $23M as of March 31. "Our first quarter results reflect strong and consistent execution across the business," said Robert Spignesi, CEO. "Strong consumable revenue drove nearly 30% growth in recurring revenue, underscoring the strength of our installed base and utilization trends. We continue to see robust customer interest in QC automation and are increasingly engaged in strategic discussions with customers on enterprise-level deployments of the Growth Direct platform and broader integration into company-wide automation strategies."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RPID?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RPID
Wall Street analysts forecast RPID stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.070
Low
8.00
Averages
8.00
High
8.00
Current: 2.070
Low
8.00
Averages
8.00
High
8.00
About RPID
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapid Micro Biosystems Secures $9.8 Million Financing
- Financing Amount: Rapid Micro Biosystems announced a financing of approximately $9.8 million, with a potential total of up to $32 million if the warrants are exercised, which will provide crucial support for the company's future success.
- Stock Offering Details: The underwritten offering includes 3,581,000 shares of Class A common stock and accompanying Series A and Series B warrants, priced at $1.955 per share, reflecting the company's last sale price on May 18, 2026.
- Executive Investment: Certain directors and officers of the company are also participating in this financing, planning to purchase 71,607 shares of Class A common stock and accompanying warrants at $1.955 per share, demonstrating management's confidence in the company's prospects.
- Future Outlook: The financing is expected to close on May 20, 2026, and if all warrants are exercised, an additional $21.7 million is anticipated, further strengthening the company's financial position and market competitiveness.
See More
Rapid Micro Biosystems Prices $9.8 Million Underwritten Offering
- Offering Size: Rapid Micro Biosystems announced the pricing of 3,581,000 shares of Class A common stock and accompanying Series A and Series B warrants at $1.955 per share, with expected gross proceeds of approximately $9.8 million, indicating the company's active engagement in capital markets and financing capabilities.
- Warrant Details: The Series A warrants have an exercise price of $1.955 per share, while Series B warrants are priced at $2.34 per share, both exercisable six months and five years post-issuance respectively, enhancing potential returns for investors and boosting market confidence in the company's future growth.
- Investor Participation: Institutional investors such as Bain Capital Life Sciences and Armistice Capital LLC are participating in the offering, reflecting strong market trust in Rapid Micro Biosystems and potentially providing support for the company's future business expansion.
- Future Outlook: If all warrants are exercised, the company expects to receive an additional $21.7 million, which will further enhance its innovation capabilities in the life sciences sector and strengthen its market competitiveness, facilitating faster product launches and increased market share.
See More
Rapid Micro Biosystems Reports Q1 Earnings Highlights
- Significant Revenue Growth: Rapid Micro Biosystems reported an 11% year-over-year revenue growth in Q1, reaching $8 million, primarily driven by system placements and recurring revenue, indicating strong market competitiveness.
- Strong Product Sales: Product revenue increased by 36% year-over-year, with consumables growing over 30%, reflecting enhanced customer utilization of GrowthDirect systems, which is expected to further drive revenue growth in the future.
- Decline in Service Revenue: Despite an improvement in gross margin to 5%, service revenue decreased from $3.1 million to $2.4 million, influenced by the timing of validation activities, which may pose pressure on overall profitability.
- Widening Net Loss: The company reported a net loss of $14.3 million, up from $11.3 million in the prior year, primarily due to non-recurring G&A costs and interest expenses, with operating expenses rising to $14.2 million, highlighting challenges in cost control.
See More
Rapid Micro Biosystems Reports Q1 Earnings with Mixed Results
- Earnings Performance: Rapid Micro Biosystems reported a Q1 GAAP EPS of -$0.31, missing expectations by $0.06, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: Despite the EPS miss, Q1 revenue reached $8 million, exceeding market expectations by $0.4 million, suggesting ongoing sales potential driven by adoption from major pharmaceutical companies.
- Future Outlook: The company has set a revenue target of $37 million to $41 million for 2026, reflecting confidence in future system placements and margin expansion, which may attract long-term investor interest.
- Market Dynamics: Rapid Micro Biosystems showcased record system placements in its Q4 2025 earnings report, and while current results are mixed, market expectations for future growth remain optimistic.
See More
Rapid Micro Biosystems Reports Record Q4 2025 Earnings and Strategic Growth
- Significant Revenue Growth: Rapid Micro Biosystems reported a record revenue of $11.3 million in Q4 2025, reflecting a 37% year-over-year increase that exceeded company expectations, marking the 13th consecutive quarter of outperforming forecasts and demonstrating strong market performance and growth potential.
- Innovative System Orders: The company secured a multisystem order from Samsung Biologics, further solidifying its market position in the pharmaceutical industry while highlighting the importance of its products in automating and modernizing critical quality and manufacturing workflows, indicating sustained growth ahead.
- Strong Recurring Revenue: For the full year 2025, recurring revenue increased by 15%, accounting for 53% of total revenue, showcasing the company's stability in product and service offerings and customer loyalty, with expectations for this trend to continue driving performance in 2026.
- Optimistic Future Outlook: The company projects total revenue for 2026 to be between $37 million and $41 million, with system placements expected to range from 30 to 38, reflecting management's confidence in future market demand and ongoing focus on profitability.
See More
Rapid Micro (RPID) Earnings Call Transcript
See More
Rapid Micro Biosystems Secures $9.8 Million Financing
- Financing Amount: Rapid Micro Biosystems announced a financing of approximately $9.8 million, with a potential total of up to $32 million if the warrants are exercised, which will provide crucial support for the company's future success.
- Stock Offering Details: The underwritten offering includes 3,581,000 shares of Class A common stock and accompanying Series A and Series B warrants, priced at $1.955 per share, reflecting the company's last sale price on May 18, 2026.
- Executive Investment: Certain directors and officers of the company are also participating in this financing, planning to purchase 71,607 shares of Class A common stock and accompanying warrants at $1.955 per share, demonstrating management's confidence in the company's prospects.
- Future Outlook: The financing is expected to close on May 20, 2026, and if all warrants are exercised, an additional $21.7 million is anticipated, further strengthening the company's financial position and market competitiveness.
See More
Rapid Micro Biosystems Prices $9.8 Million Underwritten Offering
- Offering Size: Rapid Micro Biosystems announced the pricing of 3,581,000 shares of Class A common stock and accompanying Series A and Series B warrants at $1.955 per share, with expected gross proceeds of approximately $9.8 million, indicating the company's active engagement in capital markets and financing capabilities.
- Warrant Details: The Series A warrants have an exercise price of $1.955 per share, while Series B warrants are priced at $2.34 per share, both exercisable six months and five years post-issuance respectively, enhancing potential returns for investors and boosting market confidence in the company's future growth.
- Investor Participation: Institutional investors such as Bain Capital Life Sciences and Armistice Capital LLC are participating in the offering, reflecting strong market trust in Rapid Micro Biosystems and potentially providing support for the company's future business expansion.
- Future Outlook: If all warrants are exercised, the company expects to receive an additional $21.7 million, which will further enhance its innovation capabilities in the life sciences sector and strengthen its market competitiveness, facilitating faster product launches and increased market share.
See More
Rapid Micro Biosystems Reports Q1 Earnings Highlights
- Significant Revenue Growth: Rapid Micro Biosystems reported an 11% year-over-year revenue growth in Q1, reaching $8 million, primarily driven by system placements and recurring revenue, indicating strong market competitiveness.
- Strong Product Sales: Product revenue increased by 36% year-over-year, with consumables growing over 30%, reflecting enhanced customer utilization of GrowthDirect systems, which is expected to further drive revenue growth in the future.
- Decline in Service Revenue: Despite an improvement in gross margin to 5%, service revenue decreased from $3.1 million to $2.4 million, influenced by the timing of validation activities, which may pose pressure on overall profitability.
- Widening Net Loss: The company reported a net loss of $14.3 million, up from $11.3 million in the prior year, primarily due to non-recurring G&A costs and interest expenses, with operating expenses rising to $14.2 million, highlighting challenges in cost control.
See More
Rapid Micro Biosystems Reports Q1 Earnings with Mixed Results
- Earnings Performance: Rapid Micro Biosystems reported a Q1 GAAP EPS of -$0.31, missing expectations by $0.06, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: Despite the EPS miss, Q1 revenue reached $8 million, exceeding market expectations by $0.4 million, suggesting ongoing sales potential driven by adoption from major pharmaceutical companies.
- Future Outlook: The company has set a revenue target of $37 million to $41 million for 2026, reflecting confidence in future system placements and margin expansion, which may attract long-term investor interest.
- Market Dynamics: Rapid Micro Biosystems showcased record system placements in its Q4 2025 earnings report, and while current results are mixed, market expectations for future growth remain optimistic.
See More
Rapid Micro Biosystems Reports Record Q4 2025 Earnings and Strategic Growth
- Significant Revenue Growth: Rapid Micro Biosystems reported a record revenue of $11.3 million in Q4 2025, reflecting a 37% year-over-year increase that exceeded company expectations, marking the 13th consecutive quarter of outperforming forecasts and demonstrating strong market performance and growth potential.
- Innovative System Orders: The company secured a multisystem order from Samsung Biologics, further solidifying its market position in the pharmaceutical industry while highlighting the importance of its products in automating and modernizing critical quality and manufacturing workflows, indicating sustained growth ahead.
- Strong Recurring Revenue: For the full year 2025, recurring revenue increased by 15%, accounting for 53% of total revenue, showcasing the company's stability in product and service offerings and customer loyalty, with expectations for this trend to continue driving performance in 2026.
- Optimistic Future Outlook: The company projects total revenue for 2026 to be between $37 million and $41 million, with system placements expected to range from 30 to 38, reflecting management's confidence in future market demand and ongoing focus on profitability.
See More
Rapid Micro (RPID) Earnings Call Transcript
See More
